2013年7月18日訊 /生物谷BIOON/ --雅培（Abbott）7月17日公布了優(yōu)于預(yù)期的第二季度盈利數(shù)據(jù),，這主要是因?yàn)闋I(yíng)養(yǎng)品的強(qiáng)勁需求抵消了醫(yī)療設(shè)備和仿制處方藥的銷售下降。
盡管盈利（earnings）下降,，但該公司的全年利潤(rùn)預(yù)期（full-year profit forecast）不變,，為每股1.98-2.04美元。
美國(guó)富國(guó)銀行（WELLS FARGO）分析師Larry Biegelsen在一份研究報(bào)告中稱,，雅培第二季度盈利數(shù)據(jù)優(yōu)于預(yù)期,，這主要是提高了利潤(rùn)率（profit margins）和成本控制。
營(yíng)養(yǎng)品銷售,，包括Similac嬰兒配方奶粉和Ensure成人飲品,，銷售增長(zhǎng)7.9%至17億美元，占雅培總收入的近1/3,。醫(yī)療診斷產(chǎn)品銷售額上漲1.5%至11.4億美元,，醫(yī)療設(shè)備銷售額下滑1.6%至13.6億美元，仿制藥銷售下降2.3%至12.2億美元,。
隨著最近幾周中國(guó)對(duì)可能的價(jià)格操縱和反競(jìng)爭(zhēng)行為的調(diào)查,，雅培和嬰幼兒配方奶粉競(jìng)爭(zhēng)對(duì)手均降低了產(chǎn)品價(jià)格，包括美贊臣（Mead Johnson Nutrition Co）,，達(dá)能SA（Danone SA）和雀巢（Nestle SA）,。
雅培配方奶粉在中國(guó)的年銷售約為4億美元,，僅占該公司整體銷售額的2%左右。雅培CEO Miles White周三表示,，中國(guó)政府的調(diào)查不會(huì)影響該國(guó)對(duì)配方奶粉需求的強(qiáng)勁增長(zhǎng)勢(shì)頭,。同時(shí)White稱，幸運(yùn)的是,，中國(guó)市場(chǎng)并不占該公司營(yíng)養(yǎng)業(yè)務(wù)的很大一部分,。（生物谷Bioon.com）
英文原文：Abbott profit beats forecast, nutritional products strong
Wed Jul 17, 2013 4:17pm EDT (Reuters) - Abbott Laboratories (ABT.N) reported better-than-expected second-quarter earnings on Wednesday as strong demand for nutritional products offset lower sales of medical devices and generic prescription drugs.
Despite the earnings beat, Abbott left its full-year profit forecast unchanged at $1.98 to $2.04 per share.
Results beat expectations because of improved profit margins and cost controls, Wells Fargo analyst Larry Biegelsen said in a research note.
Sales of nutritional products, including Similac infant formula and Ensure beverages for adults, rose 7.9 percent to $1.7 billion, representing almost a third of Abbott's total revenue.
Abbott and rival infant formula makers, including Mead Johnson Nutrition Co (MJN.N), Danone SA (DANO.PA) and Nestle SA (NESN.VX), have cut prices of their products in recent weeks following an investigation by China into possible price-fixing and anti-competitive behavior.
Abbott formulas have annual sales of about $400 million in China, representing about 2 percent of overall company sales.
Abbott Chief Executive Miles White on Wednesday said the investigations are unlikely to derail growing demand in China for the products.
"I think the market dynamics remain robust," White said. "And fortunately for us, China doesn't represent a disproportionately large portion of the nutrition business."
Glenn Novarro, an analyst with RBC Capital Markets, said Abbott shares had dipped as much as five percent in the past month on concerns about the China investigation and price cuts, and are a buying opportunity.
Abbott's profit margins improved during the quarter in part because the company is building its nutritionals factories closer to customers in emerging markets, said Stifel Nicolaus & Co analyst Rick Wise. "So they're reducing transportation costs."
Abbott, which in January spun off its branded prescription drugs business into a new company called AbbVie Inc (ABBV.N), earned $476 million, or 30 cents per share, from continuing operations in the quarter, up from $411 million, or 26 cents per share, a year earlier.
Excluding special items, profit was 46 cents per share, beating analysts' average estimate by 2 cents, according to Thomson Reuters I/B/E/S.
Revenue rose 2.5 percent to $5.45 billion, slightly below Wall Street expectations for $5.52 billion. Revenue would have risen 4.2 percent if not for the stronger dollar, which hurts the value of sales in overseas markets.
Sales from the company's array of medical diagnostics rose 5.3 percent to $1.14 billion.
Medical device sales slipped 1.6 percent to $1.36 billion, but that was an improvement from the almost five 5 percent decline in the first quarter.
Sales of generic drugs, which Abbott calls established pharmaceuticals, were off 2.3 percent to $1.22 billion.
"If there's a weakness in the Abbott story, it's established pharmaceuticals," said Joanne Wuensch, an analyst with BMO Capital Markets. She noted the company is making management changes in hopes of revitalizing the business segment.
Abbott shares were up 0.4 percent to $35.83 on the New York Stock Exchange.
